Nurix Therapeutics
(NASDAQ) NRIX
Nurix Therapeutics Financials at a Glance
Market Cap
$1.93B
Revenue (TTM)
$71.78M
Net Income (TTM)
-$295.28M
EPS (TTM)
-$3.16
P/E Ratio
-5.90
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Price
$18.56
Volume
5,571
Open
$18.43
Price
$18.56
Volume
5,571
Open
$18.43
Previous Close
$18.65
Daily Range
$18.36 - $18.92
52-Week Range
$8.20 - $22.50
Estimated Earnings Date
Jul 9, 2026
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Price
$18.56
Volume
5,571
Open
$18.43
Previous Close
$18.65
Daily Range
$18.36 - $18.92
52-Week Range
$8.20 - $22.50
Estimated Earnings Date
Jul 9, 2026
NRIX News
NRIX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Nurix Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
317
CEO
Arthur T. Sands, MD, PhD
Website
www.nurixtx.comHeadquarters
San Francisco, CA 94158, US
NRIX Financials
Key Financial Metrics (TTM)
Gross Margin
-1%
Operating Margin
-4%
Net Income Margin
-4%
Return on Equity
-61%
Return on Capital
-58%
Return on Assets
-46%
Earnings Yield
-16.95%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.93B
Shares Outstanding
103.41M
Volume
5.57K
Avg. Volume
1.75M
Financials (TTM)
Gross Profit
$65.12M
Operating Income
-$285.67M
EBITDA
-$244.84M
Operating Cash Flow
-$249.47M
Capital Expenditure
-$14.00M
Free Cash Flow
-$263.47M
Cash & ST Invst.
$592.94M
Total Debt
$55.73M
Nurix Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$6.25M
-66.1%
Gross Profit
-$77.89M
-52.1%
Gross Margin
-12.46%
N/A
Market Cap
$1.93B
N/A
Market Cap/Employee
$6.74M
N/A
Employees
286
N/A
Net Income
-$87.17M
-54.7%
EBITDA
-$83.40M
-54.4%
Quarterly Fundamentals
Total Cash
$540.73M
-1.6%
Total Debt
$58.66M
+120.3%
Accounts Receivable
$2.40M
N/A
Inventory
$0.00
N/A
Long Term Debt
$55.45M
+177.5%
Short Term Debt
$3.20M
-51.8%
Return on Assets
-46.42%
N/A
Return on Invested Capital
-57.97%
N/A
Free Cash Flow
-$72.96M
-13.0%
Operating Cash Flow
-$71.91M
-17.7%